I’d like to see an early P3 readout. It’s not a blind trial and the treatment is fast acting, they should have a substantial amount of data from early participants in the not too distant future.
Prof Rosenfeld noted that a major driver of share price returns would be related to vitilgo progress. This is something I do agree with, as companies approach FDA approval the market likes to push prices significantly higher. If they want the price to move higher, they should help drive it through providing additional communication related to vitiligo, and additional data to help increase the market’s confidence that this drug will indeed be a tremendous success.
Ann: Chair's letter to Shareholders, page-3
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |